Nausea and Vomiting Management

Introduction to Nausea and Vomiting Management

The National Comprehensive Cancer Network recommends palonosetron as the preferred 5-HT3 receptor antagonist for preventing nausea and vomiting in high and moderate emetic risk situations, while ondansetron is a suitable first-line agent for most general cases of nausea and vomiting in the emergency department setting 1

For chemotherapy-induced nausea and vomiting, medication selection should be based on the emetic risk of the chemotherapy regimen, with combination therapy including palonosetron, dexamethasone, and an NK1 receptor antagonist being the first choice 1
The American College of Clinical Oncology recommends 5-HT3 antagonist before each fraction + dexamethasone during first 5 fractions for high risk areas (total body, upper abdomen) 2
For moderate risk, 5-HT3 antagonist + dexamethasone is recommended, while for low risk, 5-HT3 antagonist as rescue or prophylaxis is suggested, and for minimal risk, rescue therapy with dopamine receptor antagonist or 5-HT3 antagonist is recommended 2

The American College of Clinical Oncology recommends selection based on radiation site and risk, with 5-HT3 antagonist before each fraction + dexamethasone during first 5 fractions for high risk areas (total body, upper abdomen) 2

The standard dosing for ondansetron is 4-8mg IV or oral, 30-60 minutes before anticipated nausea trigger, with a frequency not to exceed every 6-8 hours 3
Palonosetron has a longer half-life (40 hours) compared to other 5-HT3 antagonists, with a standard dosing of 0.25mg IV, and a frequency of single dose effective for up to 5 days 4
The American College of Clinical Oncology recommends single dose of palonosetron effective for up to 5 days, with dosing every second or third day may be appropriate 2

Common adverse effects of 5-HT3 antagonists include headache and constipation, while serious adverse effects include QT prolongation, which requires monitoring in cardiac patients 1
Common adverse effects of metoclopramide include sedation and akathisia, while serious adverse effects include extrapyramidal symptoms, which can be managed with slow infusion rate and diphenhydramine for akathisia 1

When efficacy is similar, cost may guide selection, with lower cost options including granisetron (2mg oral: $0.68) and ondansetron (8mg oral: $1.04), and higher cost options including palonosetron (0.25mg IV: $188.70) and aprepitant (125mg oral: $150.45) 2

Common mistakes in nausea and vomiting management include underdosing, inappropriate timing, overlooking delayed emesis, ignoring QT prolongation risk, and neglecting hydration 1